Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595080 | 1.00 | ODC1 (0.38) | ODC1LMNABLMARG1ARG2 | |
| SCHEMBL7203818 | 1.00 | ODC1 (0.38) | ODC1LMNABLMARG1ARG2 | |
| Ammonia Solution, Strong SCHEMBL27694659 | 0.98 | ODC1 (0.37) | ODC1LMNABLMARG1ARG2 | |
| SCHEMBL31325597 | 0.94 | ARG1 (0.39) | ODC1LMNABLMARG1ARG2 | |
| SCHEMBL17138101 | 0.83 | FDPS (0.41) | LMNAARG1ARG2MAPTDGAT1 | |
| SCHEMBL22854370 | 0.83 | FDPS (0.41) | LMNAARG1ARG2MAPTDGAT1 | |
| Hydrochloric Acid SCHEMBL29099886 | 0.82 | FDPS (0.39) | LMNAARG1ARG2MAPTDGAT1 | |
| SCHEMBL12138662 | 0.82 | CYP4A11 (0.46) | ARG1ARG2DGAT1GGT1THRB | |
| Hydrochloric Acid SCHEMBL29099884 | 0.82 | FDPS (0.39) | LMNAARG1ARG2MAPTDGAT1 | |
| SCHEMBL13689469 | 0.81 | CYP4F2 (0.40) | ODC1LMNABLMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
| US-4590211-A | USING HYDROXYUREA PRODURG FOR SKIN DISORDERS | THE UPJOHN COMPANY (US) | 1986-05-20 | — | — | US | disclosed |
| US-4302457-A | ACTIVATION OF PRO-DRUGS BY ULTRAVIOLET RADIATION IN TREATMENT OF SKIN DISORDERS | THE UPJOHN COMPANY (US) | 1981-11-24 | — | — | US | disclosed |
| US-4302456-A | UV RADIATION ACTIVATION OF PRO-DRUG, FOR SKIN DISEASE | THE UPJOHN COMPANY (US) | 1981-11-24 | — | — | US | disclosed |
| US-4235887-A | ADMINISTERING PRO-DRUG STEROID FOR SKIN DISORDERS | THE UPJOHN COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | ODC1 34/4885LMNA 3450/4885BLM 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.